Resposta humoral e clínica à vacinação contra leishmaniose em cães sororreagentes

Detalhes bibliográficos
Autor(a) principal: Bezerra, Lucilandia Maria
Data de Publicação: 2019
Tipo de documento: Tese
Idioma: por
Título da fonte: Repositório Institucional da UFG
dARK ID: ark:/38995/001300000ctj3
Texto Completo: http://repositorio.bc.ufg.br/tede/handle/tede/10313
Resumo: In endemic regions for visceral canine leishmaniasis (CVL), the biggest challenge currently faced is the detection of infected and asymptomatic animals, as it may be the biggest risk factor for maintenance of the infection. Therefore, the diagnosis based on more sensible and specific tests may be the possible solution to control this disease. Serological tests that can identify exposed, infected or diseased animals, such as Elisa IgG anti-Leishmania, stand out as excellent tools for detecting animals in this clinical situation in high-risk areas because of their high influence in these situations. Among the pathological clinical markers that may contribute to the detection of Leishmania infection, hematological and biochemical tests were performed. As well as the early and safe diagnosis, the treatment of infected or infectious dogs using vaccines has been of interest to researchers. In this sense, two experiments were performed. In the first, the immunotherapeutic response of a double dose anti-Leishmania vaccine (Leish-Tec®) in dogs from an endemic area for CVL was evaluated. For this purpose, 85 serum samples from asymptomatic, non-reactive and low titrated reagents (1/40 cutoff point) for RIFI tests negative to the parasitological bone marrow test were analyzed. The immune response of treated dogs was evaluated by the anti-rA2 IgG ELISA whose antigen (rA2) is part of the vaccine composition. The second evaluated the performance of a recombinant protein rK28, aiming to verify its sensitivity in detecting infected animals in endemic area. In this sense, a clinical intervention and control trial was designed to analyze the positive and negative outcomes of the animals under study. According to serological screening tests (RIFI) the animals were divided into five groups, including NRNV - unvaccinated nonreactive, n = 23; RNV - unvaccinated reagent, n = 7; NRVS - vaccinated nonreactive 1 ml, n = 22; NRVD - non-vaccinated reagent 2 ml, n = 16; and RVD - 2 ml vaccinated reagent, n = 15. After grouping, the animals were vaccinated with three applications at 21-day intervals and followed at six points of care every three months through clinical and laboratory examinations for a period of 18 months. To assess the presence or absence of parasites, bone marrow and PCR parasitological tests were performed at six and nine months after vaccination, respectively. The animal’s serological response to infection was assessed by anti-rA2 and anti-rK28 IgG levels. Hepatic and renal enzymes were tested as a condition of possible tissue damage in these organs, no changes compatible with infection or inflammation were observed, in the average of the groups in the last following point. Regarding the evaluation of responses to anti-rA2 IgG antibodies, there was a high response in the single-dose (NRVS) vaccinated groups and low response in the double dose (NRVD and RVD) vaccinated groups. When the groups were compared, there was a statistical difference between the vaccinated groups and the unvaccinated nonreactive control. The rK28 protein performed well in all groups, showing a high sensitivity in detecting positive and negative infected parasitological tests and PCR. It was concluded that the anti-leishmania vaccine (Leish-Tec®) is immunogenic by inducing high levels of anti-rA2 IgG antibodies. Double-dose vaccination reduces anti-rA2 antibody levels compared to single-dose vaccination. However, single or double dose vaccination of seropositive animals for IFAT does not provide protection against Leishmania infection. Also, detection of anti-rK28 IgG presents good performance for diagnosis of CVL in asymptomatic animals exposed in endemic area.
id UFG-2_eda2bf02ca2f4c1af9d9b46b2b3df2b0
oai_identifier_str oai:repositorio.bc.ufg.br:tede/10313
network_acronym_str UFG-2
network_name_str Repositório Institucional da UFG
repository_id_str
spelling Moura, Veridiana Maria Brianezi Dignani dehttp://lattes.cnpq.br/8773201078957745Junqueira-Kipnis, Ana Paulahttp://lattes.cnpq.br/1252262903952987Moura, Veridiana Maria Brianezi Dignani deLeandro, Mirian DortaPaiva, MoniqueMatos, Moema Pacheco ChediackPaz, Gustavo Fonteshttp://lattes.cnpq.br/6705150812075885Bezerra, Lucilandia Maria2020-01-21T11:48:58Z2019-12-13BEZERRA, L. M. Resposta humoral e clínica à vacinação contra leishmaniose em cães sororreagentes. 2019. 76 f. Tese (Doutorado em Ciência Animal) - Universidade Federal de Goiás, Goiânia, 2019.http://repositorio.bc.ufg.br/tede/handle/tede/10313ark:/38995/001300000ctj3In endemic regions for visceral canine leishmaniasis (CVL), the biggest challenge currently faced is the detection of infected and asymptomatic animals, as it may be the biggest risk factor for maintenance of the infection. Therefore, the diagnosis based on more sensible and specific tests may be the possible solution to control this disease. Serological tests that can identify exposed, infected or diseased animals, such as Elisa IgG anti-Leishmania, stand out as excellent tools for detecting animals in this clinical situation in high-risk areas because of their high influence in these situations. Among the pathological clinical markers that may contribute to the detection of Leishmania infection, hematological and biochemical tests were performed. As well as the early and safe diagnosis, the treatment of infected or infectious dogs using vaccines has been of interest to researchers. In this sense, two experiments were performed. In the first, the immunotherapeutic response of a double dose anti-Leishmania vaccine (Leish-Tec®) in dogs from an endemic area for CVL was evaluated. For this purpose, 85 serum samples from asymptomatic, non-reactive and low titrated reagents (1/40 cutoff point) for RIFI tests negative to the parasitological bone marrow test were analyzed. The immune response of treated dogs was evaluated by the anti-rA2 IgG ELISA whose antigen (rA2) is part of the vaccine composition. The second evaluated the performance of a recombinant protein rK28, aiming to verify its sensitivity in detecting infected animals in endemic area. In this sense, a clinical intervention and control trial was designed to analyze the positive and negative outcomes of the animals under study. According to serological screening tests (RIFI) the animals were divided into five groups, including NRNV - unvaccinated nonreactive, n = 23; RNV - unvaccinated reagent, n = 7; NRVS - vaccinated nonreactive 1 ml, n = 22; NRVD - non-vaccinated reagent 2 ml, n = 16; and RVD - 2 ml vaccinated reagent, n = 15. After grouping, the animals were vaccinated with three applications at 21-day intervals and followed at six points of care every three months through clinical and laboratory examinations for a period of 18 months. To assess the presence or absence of parasites, bone marrow and PCR parasitological tests were performed at six and nine months after vaccination, respectively. The animal’s serological response to infection was assessed by anti-rA2 and anti-rK28 IgG levels. Hepatic and renal enzymes were tested as a condition of possible tissue damage in these organs, no changes compatible with infection or inflammation were observed, in the average of the groups in the last following point. Regarding the evaluation of responses to anti-rA2 IgG antibodies, there was a high response in the single-dose (NRVS) vaccinated groups and low response in the double dose (NRVD and RVD) vaccinated groups. When the groups were compared, there was a statistical difference between the vaccinated groups and the unvaccinated nonreactive control. The rK28 protein performed well in all groups, showing a high sensitivity in detecting positive and negative infected parasitological tests and PCR. It was concluded that the anti-leishmania vaccine (Leish-Tec®) is immunogenic by inducing high levels of anti-rA2 IgG antibodies. Double-dose vaccination reduces anti-rA2 antibody levels compared to single-dose vaccination. However, single or double dose vaccination of seropositive animals for IFAT does not provide protection against Leishmania infection. Also, detection of anti-rK28 IgG presents good performance for diagnosis of CVL in asymptomatic animals exposed in endemic area.Em regiões endêmicas para leishmaniose visceral canina (LVC), o maior desafio enfrentado atualmente é a detecção de animais infectados e assintomáticos, uma vez que representam um grande fator de risco para a manutenção da infecção. Portanto, o diagnóstico baseado em testes mais sensíveis e específicos pode ser uma solução ao controle dessa doença. Exames sorológicos que possam identificar animais expostos, infectados ou infecciosos, como o Elisa IgG anti-Leishmania, se destacam como excelentes ferramentas para a detecção de animais nessa condição clínica nas áreas de alto risco devido a sua alta sensibilidade. Entre os marcadores clínico-patológicos que podem contribuir para a percepção de infecção por Leishmania estão os exames hematológicos e bioquímicos, os quais, associados a testes específicos, podem determinar o diagnóstico precoce e seguro; o tratamento de cães infectados ou infecciosos utilizando vacinas vem despertando interesse por pesquisadores em todo o mundo. Neste estudo foram realizados dois experimentos, sendo o primeiro a avaliação da resposta humoral e clínica de uma vacina anti-Leishmania (Leish-Tec®), em dose dupla, em cães de uma área endêmica para LVC. Para isso, foram analisadas 85 amostras de soro de animais assintomáticos, não reagentes e reagentes a baixa titulação (ponto de corte 1/40) para leishmaniose ao teste de RIFI e negativos ao teste parasitológico da medula óssea. A resposta imune dos cães tratados foi avaliada por ELISA IgG anti-rA2, cujo antígeno (rA2) faz parte da composição da vacina. O segundo, avaliou o desempenho de uma proteína recombinante rK28, objetivando verificar sua sensibilidade em detectar animais infectados em área endêmica. Nesse sentido, foi delineado um ensaio clínico de intervenção e controle para analisar os desfechos positivos e negativos dos animais do estudo. De acordo com o teste sorológico na triagem (RIFI), os animais foram distribuídos em cinco grupos, sendo NRNV - não reagente não vacinado, n=23; RNV - reagente não vacinado, n=7; NRVS - não reagente vacinado com dose única, n=22; NRVD - não reagente vacinado com dose dupla, n=16; e RVD - reagente vacinado com dose dupla, n=15. Após o agrupamento, os animais foram vacinados com três aplicações, com intervalos de 21 dias, e acompanhados em seis pontos de atendimento a cada três meses por meio de exames clínicos e laboratoriais, por um período de 18 meses. Para avaliar a presença de parasitas realizaram-se os testes parasitológico de medula óssea e PCR aos seis e nove meses após a vacinação, respectivamente. A resposta sorológica dos animais à infecção foi avaliada a partir da dosagem de IgG anti-rA2 e anti-rK28. As enzimas hepáticas e renais foram testadas como condição de possível lesão tecidual nesses órgãos, não sendo observadas alterações compatíveis com infecção ou inflamação causadas por Leishmania. Quanto a avaliação das respostas a anticorpos IgG anti-rA2, houve alta resposta no grupo vacinado com dose única (NRVS) e mais baixa naqueles vacinados com dose dupla (NRVD e RVD). Quando comparados os grupos entre si, houve diferença entre os vacinados e o controle não reagente não vacinado. Houve mais perdas de animais dos grupos controles do que nos grupos vacinados. Com relação à proteína rK28, esta apresentou bom desempenho em todos os grupos, mostrando alta sensibilidade na detecção de infectados positivos e negativos aos testes parasitológicos e de PCR. Diante disso, conclui-se que a vacina anti-leishmania (Leish-Tec®) é imunogênica ao induzir altos níveis de anticorpos IgG anti-rA2. A vacinação com dose dupla reduz os níveis de anticorpos anti-rA2 em relação a vacinação com dose única. No entanto, a vacinação em dose única ou dupla de animais soropositivos para RIFI não conferiu proteção contra a infecção por Leishmania em todos os animais. Ainda, a detecção da IgG anti-rK28 apresenta bom desempenho para diagnóstico da LVC em animais assintomáticos e expostos em área endêmica.Submitted by Luciana Ferreira (lucgeral@gmail.com) on 2020-01-17T11:48:51Z No. of bitstreams: 2 Tese - Lucilandia Maria Bezerra - 2019.pdf: 2719237 bytes, checksum: fef4778098740371464095a2203c6e7a (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2020-01-21T11:48:58Z (GMT) No. of bitstreams: 2 Tese - Lucilandia Maria Bezerra - 2019.pdf: 2719237 bytes, checksum: fef4778098740371464095a2203c6e7a (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)Made available in DSpace on 2020-01-21T11:48:58Z (GMT). No. of bitstreams: 2 Tese - Lucilandia Maria Bezerra - 2019.pdf: 2719237 bytes, checksum: fef4778098740371464095a2203c6e7a (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2019-12-13Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESapplication/pdfporUniversidade Federal de GoiásPrograma de Pós-graduação em Ciência Animal (EVZ)UFGBrasilEscola de Veterinária e Zootecnia - EVZ (RG)http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessAssintomáticoElisaVacinaLeishmania infantumDose profiláticaElisaVaccineLeishmania infantumProphylactic doseAsymptomaticMEDICINA VETERINARIA::PATOLOGIA ANIMALResposta humoral e clínica à vacinação contra leishmaniose em cães sororreagentesHumoral and clinical response to leishmaniosis seroreactive in dogs vacinatedinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesis4581960685150189167600600600600-621755211424909458250697708750753280042075167498588264571reponame:Repositório Institucional da UFGinstname:Universidade Federal de Goiás (UFG)instacron:UFGLICENSElicense.txtlicense.txttext/plain; charset=utf-82165http://repositorio.bc.ufg.br/tede/bitstreams/739a7e90-33e7-42bb-9664-15343d4e2ebb/downloadbd3efa91386c1718a7f26a329fdcb468MD51CC-LICENSElicense_urllicense_urltext/plain; charset=utf-849http://repositorio.bc.ufg.br/tede/bitstreams/8d505170-32f5-4ea6-9f8e-eff8f54aab68/download4afdbb8c545fd630ea7db775da747b2fMD52license_textlicense_texttext/html; charset=utf-80http://repositorio.bc.ufg.br/tede/bitstreams/cf36dba4-a40d-4fde-a46d-5ddbf7835c51/downloadd41d8cd98f00b204e9800998ecf8427eMD53license_rdflicense_rdfapplication/rdf+xml; charset=utf-80http://repositorio.bc.ufg.br/tede/bitstreams/893922ac-97bc-4cd2-b52c-237e26a63530/downloadd41d8cd98f00b204e9800998ecf8427eMD54ORIGINALTese - Lucilandia Maria Bezerra - 2019.pdfTese - Lucilandia Maria Bezerra - 2019.pdfapplication/pdf2719237http://repositorio.bc.ufg.br/tede/bitstreams/88758182-09c3-4989-9a72-61ffccfe4f47/downloadfef4778098740371464095a2203c6e7aMD55tede/103132020-01-21 08:48:58.363http://creativecommons.org/licenses/by-nc-nd/4.0/Acesso Abertoopen.accessoai:repositorio.bc.ufg.br:tede/10313http://repositorio.bc.ufg.br/tedeRepositório InstitucionalPUBhttp://repositorio.bc.ufg.br/oai/requesttasesdissertacoes.bc@ufg.bropendoar:2020-01-21T11:48:58Repositório Institucional da UFG - Universidade Federal de Goiás (UFG)falseTk9UQTogQ09MT1FVRSBBUVVJIEEgU1VBIFBSw5NQUklBIExJQ0VOw4dBCkVzdGEgbGljZW7Dp2EgZGUgZXhlbXBsbyDDqSBmb3JuZWNpZGEgYXBlbmFzIHBhcmEgZmlucyBpbmZvcm1hdGl2b3MuCgpMSUNFTsOHQSBERSBESVNUUklCVUnDh8ODTyBOw4NPLUVYQ0xVU0lWQQoKQ29tIGEgYXByZXNlbnRhw6fDo28gZGVzdGEgbGljZW7Dp2EsIHZvY8OqIChvIGF1dG9yIChlcykgb3UgbyB0aXR1bGFyIGRvcyBkaXJlaXRvcyBkZSBhdXRvcikgY29uY2VkZSDDoCBVbml2ZXJzaWRhZGUgClhYWCAoU2lnbGEgZGEgVW5pdmVyc2lkYWRlKSBvIGRpcmVpdG8gbsOjby1leGNsdXNpdm8gZGUgcmVwcm9kdXppciwgIHRyYWR1emlyIChjb25mb3JtZSBkZWZpbmlkbyBhYmFpeG8pLCBlL291IApkaXN0cmlidWlyIGEgc3VhIHRlc2Ugb3UgZGlzc2VydGHDp8OjbyAoaW5jbHVpbmRvIG8gcmVzdW1vKSBwb3IgdG9kbyBvIG11bmRvIG5vIGZvcm1hdG8gaW1wcmVzc28gZSBlbGV0csO0bmljbyBlIAplbSBxdWFscXVlciBtZWlvLCBpbmNsdWluZG8gb3MgZm9ybWF0b3Mgw6F1ZGlvIG91IHbDrWRlby4KClZvY8OqIGNvbmNvcmRhIHF1ZSBhIFNpZ2xhIGRlIFVuaXZlcnNpZGFkZSBwb2RlLCBzZW0gYWx0ZXJhciBvIGNvbnRlw7pkbywgdHJhbnNwb3IgYSBzdWEgdGVzZSBvdSBkaXNzZXJ0YcOnw6NvIApwYXJhIHF1YWxxdWVyIG1laW8gb3UgZm9ybWF0byBwYXJhIGZpbnMgZGUgcHJlc2VydmHDp8Ojby4KClZvY8OqIHRhbWLDqW0gY29uY29yZGEgcXVlIGEgU2lnbGEgZGUgVW5pdmVyc2lkYWRlIHBvZGUgbWFudGVyIG1haXMgZGUgdW1hIGPDs3BpYSBhIHN1YSB0ZXNlIG91IApkaXNzZXJ0YcOnw6NvIHBhcmEgZmlucyBkZSBzZWd1cmFuw6dhLCBiYWNrLXVwIGUgcHJlc2VydmHDp8Ojby4KClZvY8OqIGRlY2xhcmEgcXVlIGEgc3VhIHRlc2Ugb3UgZGlzc2VydGHDp8OjbyDDqSBvcmlnaW5hbCBlIHF1ZSB2b2PDqiB0ZW0gbyBwb2RlciBkZSBjb25jZWRlciBvcyBkaXJlaXRvcyBjb250aWRvcyAKbmVzdGEgbGljZW7Dp2EuIFZvY8OqIHRhbWLDqW0gZGVjbGFyYSBxdWUgbyBkZXDDs3NpdG8gZGEgc3VhIHRlc2Ugb3UgZGlzc2VydGHDp8OjbyBuw6NvLCBxdWUgc2VqYSBkZSBzZXUgCmNvbmhlY2ltZW50bywgaW5mcmluZ2UgZGlyZWl0b3MgYXV0b3JhaXMgZGUgbmluZ3XDqW0uCgpDYXNvIGEgc3VhIHRlc2Ugb3UgZGlzc2VydGHDp8OjbyBjb250ZW5oYSBtYXRlcmlhbCBxdWUgdm9jw6ogbsOjbyBwb3NzdWkgYSB0aXR1bGFyaWRhZGUgZG9zIGRpcmVpdG9zIGF1dG9yYWlzLCB2b2PDqiAKZGVjbGFyYSBxdWUgb2J0ZXZlIGEgcGVybWlzc8OjbyBpcnJlc3RyaXRhIGRvIGRldGVudG9yIGRvcyBkaXJlaXRvcyBhdXRvcmFpcyBwYXJhIGNvbmNlZGVyIMOgIFNpZ2xhIGRlIFVuaXZlcnNpZGFkZSAKb3MgZGlyZWl0b3MgYXByZXNlbnRhZG9zIG5lc3RhIGxpY2Vuw6dhLCBlIHF1ZSBlc3NlIG1hdGVyaWFsIGRlIHByb3ByaWVkYWRlIGRlIHRlcmNlaXJvcyBlc3TDoSBjbGFyYW1lbnRlIAppZGVudGlmaWNhZG8gZSByZWNvbmhlY2lkbyBubyB0ZXh0byBvdSBubyBjb250ZcO6ZG8gZGEgdGVzZSBvdSBkaXNzZXJ0YcOnw6NvIG9yYSBkZXBvc2l0YWRhLgoKQ0FTTyBBIFRFU0UgT1UgRElTU0VSVEHDh8ODTyBPUkEgREVQT1NJVEFEQSBURU5IQSBTSURPIFJFU1VMVEFETyBERSBVTSBQQVRST0PDjU5JTyBPVSAKQVBPSU8gREUgVU1BIEFHw4pOQ0lBIERFIEZPTUVOVE8gT1UgT1VUUk8gT1JHQU5JU01PIFFVRSBOw4NPIFNFSkEgQSBTSUdMQSBERSAKVU5JVkVSU0lEQURFLCBWT0PDiiBERUNMQVJBIFFVRSBSRVNQRUlUT1UgVE9ET1MgRSBRVUFJU1FVRVIgRElSRUlUT1MgREUgUkVWSVPDg08gQ09NTyAKVEFNQsOJTSBBUyBERU1BSVMgT0JSSUdBw4fDlUVTIEVYSUdJREFTIFBPUiBDT05UUkFUTyBPVSBBQ09SRE8uCgpBIFNpZ2xhIGRlIFVuaXZlcnNpZGFkZSBzZSBjb21wcm9tZXRlIGEgaWRlbnRpZmljYXIgY2xhcmFtZW50ZSBvIHNldSBub21lIChzKSBvdSBvKHMpIG5vbWUocykgZG8ocykgCmRldGVudG9yKGVzKSBkb3MgZGlyZWl0b3MgYXV0b3JhaXMgZGEgdGVzZSBvdSBkaXNzZXJ0YcOnw6NvLCBlIG7Do28gZmFyw6EgcXVhbHF1ZXIgYWx0ZXJhw6fDo28sIGFsw6ltIGRhcXVlbGFzIApjb25jZWRpZGFzIHBvciBlc3RhIGxpY2Vuw6dhLgo=
dc.title.eng.fl_str_mv Resposta humoral e clínica à vacinação contra leishmaniose em cães sororreagentes
dc.title.alternative.por.fl_str_mv Humoral and clinical response to leishmaniosis seroreactive in dogs vacinated
title Resposta humoral e clínica à vacinação contra leishmaniose em cães sororreagentes
spellingShingle Resposta humoral e clínica à vacinação contra leishmaniose em cães sororreagentes
Bezerra, Lucilandia Maria
Assintomático
Elisa
Vacina
Leishmania infantum
Dose profilática
Elisa
Vaccine
Leishmania infantum
Prophylactic dose
Asymptomatic
MEDICINA VETERINARIA::PATOLOGIA ANIMAL
title_short Resposta humoral e clínica à vacinação contra leishmaniose em cães sororreagentes
title_full Resposta humoral e clínica à vacinação contra leishmaniose em cães sororreagentes
title_fullStr Resposta humoral e clínica à vacinação contra leishmaniose em cães sororreagentes
title_full_unstemmed Resposta humoral e clínica à vacinação contra leishmaniose em cães sororreagentes
title_sort Resposta humoral e clínica à vacinação contra leishmaniose em cães sororreagentes
author Bezerra, Lucilandia Maria
author_facet Bezerra, Lucilandia Maria
author_role author
dc.contributor.advisor1.fl_str_mv Moura, Veridiana Maria Brianezi Dignani de
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/8773201078957745
dc.contributor.advisor-co1.fl_str_mv Junqueira-Kipnis, Ana Paula
dc.contributor.advisor-co1Lattes.fl_str_mv http://lattes.cnpq.br/1252262903952987
dc.contributor.referee1.fl_str_mv Moura, Veridiana Maria Brianezi Dignani de
dc.contributor.referee2.fl_str_mv Leandro, Mirian Dorta
dc.contributor.referee3.fl_str_mv Paiva, Monique
dc.contributor.referee4.fl_str_mv Matos, Moema Pacheco Chediack
dc.contributor.referee5.fl_str_mv Paz, Gustavo Fontes
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/6705150812075885
dc.contributor.author.fl_str_mv Bezerra, Lucilandia Maria
contributor_str_mv Moura, Veridiana Maria Brianezi Dignani de
Junqueira-Kipnis, Ana Paula
Moura, Veridiana Maria Brianezi Dignani de
Leandro, Mirian Dorta
Paiva, Monique
Matos, Moema Pacheco Chediack
Paz, Gustavo Fontes
dc.subject.por.fl_str_mv Assintomático
Elisa
Vacina
Leishmania infantum
Dose profilática
topic Assintomático
Elisa
Vacina
Leishmania infantum
Dose profilática
Elisa
Vaccine
Leishmania infantum
Prophylactic dose
Asymptomatic
MEDICINA VETERINARIA::PATOLOGIA ANIMAL
dc.subject.eng.fl_str_mv Elisa
Vaccine
Leishmania infantum
Prophylactic dose
Asymptomatic
dc.subject.cnpq.fl_str_mv MEDICINA VETERINARIA::PATOLOGIA ANIMAL
description In endemic regions for visceral canine leishmaniasis (CVL), the biggest challenge currently faced is the detection of infected and asymptomatic animals, as it may be the biggest risk factor for maintenance of the infection. Therefore, the diagnosis based on more sensible and specific tests may be the possible solution to control this disease. Serological tests that can identify exposed, infected or diseased animals, such as Elisa IgG anti-Leishmania, stand out as excellent tools for detecting animals in this clinical situation in high-risk areas because of their high influence in these situations. Among the pathological clinical markers that may contribute to the detection of Leishmania infection, hematological and biochemical tests were performed. As well as the early and safe diagnosis, the treatment of infected or infectious dogs using vaccines has been of interest to researchers. In this sense, two experiments were performed. In the first, the immunotherapeutic response of a double dose anti-Leishmania vaccine (Leish-Tec®) in dogs from an endemic area for CVL was evaluated. For this purpose, 85 serum samples from asymptomatic, non-reactive and low titrated reagents (1/40 cutoff point) for RIFI tests negative to the parasitological bone marrow test were analyzed. The immune response of treated dogs was evaluated by the anti-rA2 IgG ELISA whose antigen (rA2) is part of the vaccine composition. The second evaluated the performance of a recombinant protein rK28, aiming to verify its sensitivity in detecting infected animals in endemic area. In this sense, a clinical intervention and control trial was designed to analyze the positive and negative outcomes of the animals under study. According to serological screening tests (RIFI) the animals were divided into five groups, including NRNV - unvaccinated nonreactive, n = 23; RNV - unvaccinated reagent, n = 7; NRVS - vaccinated nonreactive 1 ml, n = 22; NRVD - non-vaccinated reagent 2 ml, n = 16; and RVD - 2 ml vaccinated reagent, n = 15. After grouping, the animals were vaccinated with three applications at 21-day intervals and followed at six points of care every three months through clinical and laboratory examinations for a period of 18 months. To assess the presence or absence of parasites, bone marrow and PCR parasitological tests were performed at six and nine months after vaccination, respectively. The animal’s serological response to infection was assessed by anti-rA2 and anti-rK28 IgG levels. Hepatic and renal enzymes were tested as a condition of possible tissue damage in these organs, no changes compatible with infection or inflammation were observed, in the average of the groups in the last following point. Regarding the evaluation of responses to anti-rA2 IgG antibodies, there was a high response in the single-dose (NRVS) vaccinated groups and low response in the double dose (NRVD and RVD) vaccinated groups. When the groups were compared, there was a statistical difference between the vaccinated groups and the unvaccinated nonreactive control. The rK28 protein performed well in all groups, showing a high sensitivity in detecting positive and negative infected parasitological tests and PCR. It was concluded that the anti-leishmania vaccine (Leish-Tec®) is immunogenic by inducing high levels of anti-rA2 IgG antibodies. Double-dose vaccination reduces anti-rA2 antibody levels compared to single-dose vaccination. However, single or double dose vaccination of seropositive animals for IFAT does not provide protection against Leishmania infection. Also, detection of anti-rK28 IgG presents good performance for diagnosis of CVL in asymptomatic animals exposed in endemic area.
publishDate 2019
dc.date.issued.fl_str_mv 2019-12-13
dc.date.accessioned.fl_str_mv 2020-01-21T11:48:58Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv BEZERRA, L. M. Resposta humoral e clínica à vacinação contra leishmaniose em cães sororreagentes. 2019. 76 f. Tese (Doutorado em Ciência Animal) - Universidade Federal de Goiás, Goiânia, 2019.
dc.identifier.uri.fl_str_mv http://repositorio.bc.ufg.br/tede/handle/tede/10313
dc.identifier.dark.fl_str_mv ark:/38995/001300000ctj3
identifier_str_mv BEZERRA, L. M. Resposta humoral e clínica à vacinação contra leishmaniose em cães sororreagentes. 2019. 76 f. Tese (Doutorado em Ciência Animal) - Universidade Federal de Goiás, Goiânia, 2019.
ark:/38995/001300000ctj3
url http://repositorio.bc.ufg.br/tede/handle/tede/10313
dc.language.iso.fl_str_mv por
language por
dc.relation.program.fl_str_mv 4581960685150189167
dc.relation.confidence.fl_str_mv 600
600
600
600
dc.relation.department.fl_str_mv -6217552114249094582
dc.relation.cnpq.fl_str_mv 5069770875075328004
dc.relation.sponsorship.fl_str_mv 2075167498588264571
dc.rights.driver.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Goiás
dc.publisher.program.fl_str_mv Programa de Pós-graduação em Ciência Animal (EVZ)
dc.publisher.initials.fl_str_mv UFG
dc.publisher.country.fl_str_mv Brasil
dc.publisher.department.fl_str_mv Escola de Veterinária e Zootecnia - EVZ (RG)
publisher.none.fl_str_mv Universidade Federal de Goiás
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFG
instname:Universidade Federal de Goiás (UFG)
instacron:UFG
instname_str Universidade Federal de Goiás (UFG)
instacron_str UFG
institution UFG
reponame_str Repositório Institucional da UFG
collection Repositório Institucional da UFG
bitstream.url.fl_str_mv http://repositorio.bc.ufg.br/tede/bitstreams/739a7e90-33e7-42bb-9664-15343d4e2ebb/download
http://repositorio.bc.ufg.br/tede/bitstreams/8d505170-32f5-4ea6-9f8e-eff8f54aab68/download
http://repositorio.bc.ufg.br/tede/bitstreams/cf36dba4-a40d-4fde-a46d-5ddbf7835c51/download
http://repositorio.bc.ufg.br/tede/bitstreams/893922ac-97bc-4cd2-b52c-237e26a63530/download
http://repositorio.bc.ufg.br/tede/bitstreams/88758182-09c3-4989-9a72-61ffccfe4f47/download
bitstream.checksum.fl_str_mv bd3efa91386c1718a7f26a329fdcb468
4afdbb8c545fd630ea7db775da747b2f
d41d8cd98f00b204e9800998ecf8427e
d41d8cd98f00b204e9800998ecf8427e
fef4778098740371464095a2203c6e7a
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFG - Universidade Federal de Goiás (UFG)
repository.mail.fl_str_mv tasesdissertacoes.bc@ufg.br
_version_ 1815172636119924736